Drug Database
HE

hepatitis-B human immunoglobulin

✓ Approved

Sichuan Yuanda Shuyang Pharmaceutical Co Ltd · 多克隆抗体 · 多克隆抗体

什么是 hepatitis-B human immunoglobulin?

hepatitis-B human immunoglobulin 是一种多克隆抗体,由Sichuan Yuanda Shuyang Pharmaceutical Co Ltd研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

公司Sichuan Yuanda Shuyang Pharmaceutical Co Ltd
药物类别多克隆抗体, 抗体
给药途径Injectable (Others)
状态Approved

治疗适应症

hepatitis-B human immunoglobulin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsHepatitis B✓ Approved

相关研究文献

PubMedPakistan journal of medical sciences2026-11-17

ELISA screening results for HAV, HBV, HCV, HIV: A retrospective study.

Goktas Olgun O, Deniz Ismail Emre IE, Ercan Ilker I

To retrospectively evaluate the hepatitis A, B, C, and human immunodeficiency virus screening results using the ELISA method in primary care. This study was conducted retrospectively using the available recorded data of individuals registered with the Bursa Uludag University Family Health Center who underwent ELISA measurement between January 2020 to December 2024. The study included data from a total of 2,918 individuals over the age of 18 who met the inclusion criteria. In statistical comparisons, α was taken as 0.05. Data analysis was performed using the IBM SPSS Statistics 28 statistical package program. Of the 2918 individuals who participated in the study, 1528 (52.4%) were female, and 1390 (47.6%) were male. The median age of the participants was 24 (18-83). Of the participants, 1355 (46.4%) were healthcare workers, while 1563 (53.6%) were not. Hospital referrals were made in 37 (1.3%) individuals, while 2881 (98.7%) were not referred. Anti-HAVIgM and HBsAg positivity was significantly higher in the non-healthcare worker group compared to the healthcare worker group (p=0.013, p=0.038). Anti-HBcIgG, anti-HBs positivity, and Hepatitis-B vaccination were higher in the healthcare worker group (p<0.001). There was a statistically significant difference between HBsAg and anti-HBs (p<0.001). Hospital referral rates were higher in those positive for Hepatitis A, B, C, and HIV antibodies, while they were significantly lower in those with anti-HBs positivity and those vaccinated against Hepatitis-B (p<0.001). ELISA screenings, Hepatitis-B antibody levels and vaccination status were higher in healthcare workers, while Hepatitis-B antigen levels were higher in non-healthcare workers. Hospital referral rates were also higher in those with high Hepatitis A, B, C, and HIV antibody levels. Our ELISA screening results for infections in family medicine are important for diagnosis, treatment, follow-up, and referral to other clinics.

PMID 43042247
阅读全文 →
PubMedHepatology forum2026-11-17

Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review.

Zhu Kai K, Wu Eric E, Tam Benson B, Yoshida Eric M EM et al.

We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.

PMID 43042239
阅读全文 →
PubMedBMC gastroenterology2026-11-17

Incidence of liver cancer and decompensated cirrhosis amongst hepatitis B and C notifications in Tasmania- a data linkage study.

Ibegu Maria M, Le Tuan Nguyen Anh A, Stephens Nicola N, de Graaff Barbara B

Liver cancer is a leading cause of cancer-related death globally, with both incidence and mortality rates rising sharply in Australia over the past three decades. Chronic hepatitis B and C are major contributors to liver cancer, and its common precursor, decompensated cirrhosis. This study assessed the incidence of liver cancer and decompensated cirrhosis among individuals with hepatitis B and C in Tasmania. A retrospective population-based study was conducted using linked datasets. The cohort included all individuals with a notification for hepatitis B and/or C in Tasmania from 1995 to 2022. Cases were linked to the Tasmanian Cancer Register and admitted patient data from Tasmanian public hospitals. Incidence rates per 1,000 person-years were calculated for liver cancer and decompensated cirrhosis. Between 1995 and 2022, 1,280 hepatitis B (55.5% male) and 6,658 hepatitis C (64.3% male) notifications were recorded in Tasmania. A total of 145 liver cancer registrations and 270 decompensated cirrhosis-related admissions were observed. Among individuals with hepatitis B, the incidence rates were 5.39 per 1,000 person-years for liver cancer and 3.00 per 1,000 person-years for decompensated cirrhosis. Among those with hepatitis C, corresponding rates were 2.33 and 5.02 per 1,000 person-years. While the number of liver-related outcomes was relatively low and did not support more detailed analyses, a trend towards higher incidence rates was observed over the study period. These findings highlight the burden of liver-related complications among individuals with hepatitis B and C in Tasmania. Liver cancer was more common among those with hepatitis B, while decompensated cirrhosis was more frequent among those with hepatitis C. Observed trends should be interpreted cautiously, as they may reflect changes in population characteristics, surveillance, and healthcare engagement. Strengthening testing, treatment uptake, and long-term monitoring is essential to reduce the burden of advanced liver disease in this regional setting.

PMID 43040487
阅读全文 →
PubMedHepatology forum2026-11-17

Hepatitis B surface antigen seroclearance after nucleos(t)ide analogue discontinuation in non-cirrhotic patients with chronic hepatitis B.

Melekoglu Ellik Zeynep Z, Sah Unal Fatma Tugce FT, Koc Ozge O, Tunc Esra E et al.

This study aimed to evaluate the clinical outcomes following the discontinuation of nucleos(t)ide analogue (NA) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). This single-center retrospective cohort study included 146 non-cirrhotic patients with CHB who achieved long-term viral suppression under NA treatment. Seventy-three patients discontinued NA treatment, while a historical age- and sex-matched control group consisted of 73 patients who continued NA treatment. Hepatitis B surface antigen (HBsAg) seroclearance occurred in eight patients (11%) in the treatment-discontinuation group, while none was observed in the treatment-continued group (p = 0.004). The cumulative probability of HBsAg loss was 16.9% at month 120 after NA discontinuation. Firth-penalized Cox regression analysis identified younger age (<50 years) at treatment discontinuation (p=0.023) and elevated baseline serum AST levels (p=0.018) as independent predictors of HBsAg seroclearance. Seventy-five percent of these patients experienced HBsAg seroconversion to hepatitis B surface antibody (anti-HBs). After NA discontinuation, 67% of the patients (49/73) in the treatment-discontinuation group experienced virological relapse. Of these, 29 developed clinical relapse and reinitiated antiviral treatment, while the remaining 20 patients continued follow-up without antiviral therapy. Most clinical relapses (72%) occurred within the first 3 months after treatment discontinuation. Virological relapse did not occur in the other 24 patients. Overall, 44 patients in the treatment-discontinuation group (60%) did not require retreatment during follow-up. Discontinuation of long-term NA treatment in selected HBeAg-negative patients was associated with HBsAg seroclearance and may contribute to a functional cure. Close post-discontinuation surveillance remains essential for early detection and management of clinical relapse.

PMID 43042248
阅读全文 →
PubMedPakistan journal of medical sciences2026-11-17

A case of Atypical Occult Hepatitis B Infection (OBI) with HBsAg Negativity and High Anti-HBs Titer: Clinical implications.

Duan Lin L, Li Yiyang Y, Xing Sining S, Liu Meichen M et al.

A 72 years old male patient was admitted presenting with upper abdominal distension and pain for one day. He had a 20-year history of hypertension and a 10 years history of hepatitis B, which he reported had been cured. Laboratory tests revealed a distinctive serological profile characterized by HBsAg negativity, anti-HBs positivity (714.2 mIU/ml), anti-HBe positivity, and anti-HBc positivity. However, HBV DNA was tested positive (5.962×102 IU/mL). The imaging studies revealed a heterogeneous space-occupying lesion in the left hepatic lobe. This case challenges the conventional perception that "a high anti-HBs titer is indicative of protective immunity and successful viral clearance". The patient underwent resection of the lesion and received regular follow-up postoperatively.

PMID 43042112
阅读全文 →
PubMedImmunity, inflammation and disease2026-11-17

CLEC18 Suppressed by ER Stress in Chronic Hepatitis B Virus Infection and Signals an Immune Recovery Biomarker After Seroconversion.

Hsu Jye-Lin JL, Tsai Tsung-Yu TY, Hsieh Shie-Liang SL, Peng Cheng-Yuan CY

CLEC18 is a novel C-type lectin highly expressed in the liver and localized to the endoplasmic reticulum (ER). The previous study showed that plasma CLEC18 levels are reduced in patients with chronic hepatitis B virus (HBV) infection and are associated with treatment response to nucleos(t)ide analog (NUC) therapy. HBV is known to induce ER stress to facilitate viral replication and subvert host immune responses; However, the mechanism by which ER stress contributes to CLEC18 downregulation and impaired secretion remains unclear. We retrospectively analyzed 121 patients across different clinical phases of chronic HBV infection and 17 healthy controls. Plasma CLEC18 levels were measured and compared among HBV phases. In parallel, Huh7 hepatoma cells were transfected with HBV plasmids, and ER stress was induced using tunicamycin and thapsigargin to assess unfolded protein response activation and intracellular versus extracellular CLEC18 levels. Plasma CLEC18 levels were significantly higher during the immune-clearance phase and after hepatitis B surface antigen (HBsAg) seroconversion than in the immune-tolerance phase. In Huh7 cells, HBV transfection or chemical induction of ER stress activated phospho-eIF2α, ATF4, and XBP-1 s and led to intracellular accumulation of CLEC18 with a concomitant reduction in its secretion into the supernatant. Chronic HBV infection appears to suppress circulating CLEC18 by ER stress-mediated impairment of its secretion, while restoration of viral control is accompanied by recovery of plasma CLEC18. CLEC18 may thus serve as a biomarker of immune recovery in chronic HBV infection, and targeting ER stress to restore CLEC18 trafficking could be a potential therapeutic approach.

PMID 43043098
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hepatitis-B human immunoglobulin